ASTH or CHE: Which Is the Better Value Stock Right Now?

Astrana Health, Inc. (ASTH) is identified as a superior value stock compared to Chemed (CHE) within the Medical - Outpatient and Home Healthcare sector. ASTH holds a Zacks Rank #1 (Strong Buy) due to positive earnings estimate revisions, contrasting with CHE's Zacks Rank #4 (Sell). Valuation metrics further support ASTH, which exhibits a lower forward P/E of 15.66 (vs. CHE's 20.47), a PEG ratio of 0.91 (vs. CHE's 2.09), and a P/B ratio of 1.85 (vs. CHE's 5.84), resulting in an 'A' Value grade for ASTH compared to CHE's 'C'.

Analysis

Within the Medical - Outpatient and Home Healthcare sector, Astrana Health, Inc. (ASTH) presents a significantly more compelling value proposition than Chemed (CHE) based on key fundamental and momentum indicators. ASTH holds a Zacks Rank #1 (Strong Buy), signifying a trend of positive earnings estimate revisions and an improving outlook. This contrasts sharply with CHE's Zacks Rank #4 (Sell). The valuation disparity is stark: ASTH trades at a forward P/E of 15.66, while CHE is higher at 20.47. More critically, ASTH's PEG ratio of 0.91 suggests its stock price is potentially undervalued relative to its expected earnings growth, whereas CHE's PEG of 2.09 indicates a premium valuation. Further supporting ASTH's case is its Price-to-Book (P/B) ratio of 1.85, which is substantially lower than CHE's P/B of 5.84. These metrics culminate in a top-tier Value grade of 'A' for ASTH, compared to a mediocre 'C' for CHE, reinforcing the assessment that ASTH is the superior value-oriented investment at this time.

Key Decisions for Investors

• Value-oriented investors should consider Astrana Health (ASTH) as a primary candidate for investment in the outpatient healthcare space, given its strong buy rating and attractive valuation metrics relative to its growth prospects.
• Holders of Chemed (CHE) should re-evaluate their positions in light of its sell rating and valuation multiples, particularly a PEG ratio over 2.0, which suggests the stock may be overvalued.
• For those executing relative value strategies, the provided data suggests a potential pairs trade of long ASTH and short CHE to capitalize on the divergent fundamental outlooks and valuations.